SANM reports Q3 results on July 30 with the stock trading near elevated levels — and a cluster of insider selling in the rearview mirror that sets up an interesting test of executive confidence versus market momentum.
The insider activity is the most striking feature of the current setup. In the two months before this print, nearly every level of the company's leadership sold shares. Founder and Chairman/CEO Jure Sola offloaded 118,368 shares in early May for roughly $27 million. The CFO sold twice in late May for a combined ~$2.7 million. An Executive Vice President sold across four separate transactions. Net insider disposals over the 90 days through late May totalled around $38.4 million — a notably broad and consistent pattern of distribution, not a single executive cashing out. The stock has since pulled back about 12% from those levels to $208.90, though it has recovered modestly over the past week, up around 3.5%.
Short interest offers little support for the bear case in isolation. At 2.5% of the free float — with borrowing costs running near 0.45% and borrow availability extraordinarily loose (roughly 9,650% of shares short, meaning the lending pool dwarfs actual demand) — there is no meaningful squeeze dynamic at play. The short score edged up to 30.7 this week from around 28, driven by a 65% jump in shares short in a single session on July 24, but the absolute level remains low. Options positioning is equally unexcited: the put/call ratio at 0.58 is almost exactly in line with its 20-day average, producing a z-score near zero. Neither options traders nor short sellers are positioning for a dramatic move.
The analyst debate reflects a similarly divided picture. The consensus mean target of $240 — roughly 15% above the current price — implies the Street still sees upside, though the most recent bellwether action came from JP Morgan, which initiated coverage in March at Neutral with a $145 target, well below where the stock now trades. That target looks stale given the stock's subsequent run, but the Neutral rating signals limited conviction among the more cautious voices. Argus Research maintained a Buy in January with a $200 target, now also below market. Valuation multiples have compressed over the past month — the P/E has fallen around 2.5 turns to roughly 17x, and price-to-book has shed about half a point — which could be read as the market moderating the premium rather than abandoning the story. Peers in electronic manufacturing services had a rougher session on Monday: FLEX dropped more than 7% in a single day, and JBL and BHE each fell around 3%, while SANM gained fractionally — a relative resilience that mirrors the stock's recent outperformance.
The July 30 print will test whether the company's defense and industrial mix can sustain the margins that drove a 12% post-earnings rally after the April quarter — and whether the board's own selling ahead of that level represents a verdict on fair value or simply routine diversification.
See the live data behind this article on ORTEX.
Open SANM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
